# Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

> **NCT00743379** · PHASE1,PHASE2 · COMPLETED · sponsor: **Threshold Pharmaceuticals** · enrollment: 71 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Prostate Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** TH-302

## Key facts

- **NCT ID:** NCT00743379
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2013-07
- **Final completion:** 2014-03
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2015-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743379, "Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00743379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*